This Article Full Text (PDF) All Versions of this Article: 0269881106068395v1 0269881106068395v2 21/6/588    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by McKendrick, J. Articles by Chinn, C. Search for Related Content PubMed PubMed Citation Articles by McKendrick, J. Articles by Chinn, C. Social Bookmarking                         What's this?

Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom

Eli Lilly and Company Ltd, Basingstoke, UK, mckendrick_jan{at}LiLLy.com

K.H. Cerri

Eli Lilly and Company Ltd, Basingstoke, UK

A. LLoyd

Fourth Hurdle Consulting Ltd, London, UK

A. D'AusiLio

Fourth Hurdle Consulting Ltd, London, UK

S. Dando

Eli Lilly and Company Ltd, Basingstoke, UK

C. Chinn

Eli Lilly and Company Ltd, Basingstoke, UK

This study evaLuated the cost effectiveness of oLanzapine compared with lithium as maintenance therapy for patients with bipoLar I disorder (BP1) in the UK.

A Markov model was deveLoped to assess costs and outcomes from the perspective of the UK National HeaLth Service over a 1-year period. Patients enter the modeL after stabilization of a manic episode and are then treated with olanzapine or lithium. Using the findings of a recent randomized clinical trial, the modeL considers the monthly risk of manic or depressive episodes and of dropping out from allocated therapy. Health care resources associated with acute episodes were derived primarily from a recent UK chart review. Costs of maintenance therapy and monitoring were also considered. Key factors influencing cost effectiveness were identified and included in a stochastic sensitivity analysis.

The model estimated that, compared to lithium, olanzapine significantly reduced the annual number of acute mood episodes per patient from 0.81 to 0.58 (difference —0.23; 95% CI: —0.34, —0.12). Per patient average annual care costs fell by £799 (95% CI: —£1,824, £59) driven by reduced inpatient days — but the cost difference was not statistically significant. Sensitivity analysis found the results to be robust to plausible variation in the model's parameters.

The model estimated that using olanzapine instead of lithium as maintenance therapy for BP1 would significantly reduce the rate of acute mood events resulting in reduced hospital costs. Based on available evidence, there is a high likelihood that olanzapine would reduce costs of care compared to lithium.

Key Words: bipolar disorder • cost-effectiveness • olanzapine

This version was published on August 1, 2007

Journal of Psychopharmacology, Vol. 21, No. 6, 588-596 (2007)
DOI: 10.1177/0269881106068395


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?